This study is looking at using different experimental treatment methods for children diagnosed with Acute Myeloid Leukemia (AML) and Down Syndrome (DS) based on how well they respond to their first treatment.
This study is trying to determine the best amount of treatment patients should receive by dividing patients into standard risk and high risk subgroups based on how well they responded to their first treatment. Standard risk patients will receive less treatment than children with DS AML receive today, in the hope that they can be successfully treated with less treatment, decreasing side effects. High risk patients will be treated with higher doses of chemotherapy.
What we're hoping for
We hope to find out if standard risk DS AML can be treated with less treatment and still have successful outcomes and if subjects with high risk DS AML can be successfully treated with stronger chemotherapy.
ClinicalTrials.gov Identifier: NCT02521493